

# John M Kane

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3654456/publications.pdf](https://exaly.com/author-pdf/3654456/publications.pdf)

Version: 2025-02-01

243  
papers

18,028  
citations

8949

69  
h-index

11110

128  
g-index

274  
all docs

274  
docs citations

274  
times ranked

14540  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tardive dyskinesia versus tardive syndrome. What is in a name?. <i>Parkinsonism and Related Disorders</i> , 2025, 133, 107295.	2.4	1
2	Examining the Effectiveness of a Digital Media Campaign at Reducing the Duration of Untreated Psychosis in New York State: Results From a Stepped-wedge Randomized Controlled Trial. <i>Schizophrenia Bulletin</i> , 2024, 50, 705-716.	4.3	0
3	Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2024, 50, 496-512.	4.3	9
4	Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database. <i>Drug Safety</i> , 2024, 47, 745-757.	3.2	2
5	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 4064-4082.	4.6	20
6	Relapse prevention through health technology program reduces hospitalization in schizophrenia. <i>Psychological Medicine</i> , 2023, 53, 4114-4120.	4.6	8
7	The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2023, Volume 19, 531-545.	2.5	15
8	Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic. <i>Neuropsychiatric Disease and Treatment</i> , 2023, Volume 19, 623-634.	2.5	1
9	A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 2: Negative Symptoms in Schizophrenia [Podcast]. <i>Neuropsychiatric Disease and Treatment</i> , 2023, Volume 19, 1339-1345.	2.5	0
10	A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 1: Addressing Daily Functioning and Cognitive Impairments Associated with Schizophrenia [Podcast]. <i>Neuropsychiatric Disease and Treatment</i> , 2023, Volume 19, 1331-1338.	2.5	0
11	Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options. <i>CNS Drugs</i> , 2023, 37, 499-512.	6.8	3
12	Changes in telepsychiatry regulations during the COVID-19 pandemic: 17 countries and regions' approaches to an evolving healthcare landscape. <i>Psychological Medicine</i> , 2022, 52, 2606-2613.	4.6	83
13	Development of a computerized adaptive diagnostic screening tool for psychosis. <i>Schizophrenia Research</i> , 2022, 245, 116-121.	2.4	10
14	Striatal functional connectivity in psychosis relapse: A hypothesis generating study. <i>Schizophrenia Research</i> , 2022, 243, 342-348.	2.4	9
15	Core clinical manifestations of clozapine-related DRESS syndrome: A network analysis. <i>Schizophrenia Research</i> , 2022, 243, 451-453.	2.4	6
16	Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. <i>Schizophrenia Bulletin</i> , 2022, 48, 296-306.	4.3	25
17	Prevalence of impaired kidney function in patients with long-term lithium treatment: A systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2022, 24, 264-274.	2.5	40
18	Acoustic and Facial Features From Clinical Interviews for Machine Learning-Based Psychiatric Diagnosis: Algorithm Development. <i>JMIR Mental Health</i> , 2022, 9, e24699.	5.5	18

#	ARTICLE	IF	CITATIONS
19	Digital and Mobile Health Technology in Collaborative Behavioral Health Care: Scoping Review. JMIR Mental Health, 2022, 9, e30810.	5.5	12
20	Psychotropic Medication Use Is Associated With Greater 1-Year Incidence of Dementia After COVID-19 Hospitalization. Frontiers in Medicine, 2022, 9, .	2.7	8
21	An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 537-540.	2.9	7
22	Post-acute college student satisfaction with telepsychiatry during the COVID-19 pandemic. Journal of Psychiatric Research, 2022, 151, 1-7.	3.1	7
23	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	144
24	Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome. Expert Opinion on Drug Safety, 2022, 21, 585-587.	2.8	7
25	Digital Strategies to Accelerate Help-Seeking in Youth With Psychiatric Concerns in New York State. Frontiers in Psychiatry, 2022, 13, .	2.7	5
26	Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. European Neuropsychopharmacology, 2022, 60, 25-37.	0.9	20
27	The pharmacological treatment of schizophrenia: How far have we come?. Psychiatry and Clinical Neurosciences Reports, 2022, 1, .	0.5	2
28	Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit. Journal of Psychopharmacology, 2022, 36, 1036-1040.	5.8	3
29	Digital Technology in Psychiatry: Survey Study of Clinicians. JMIR Formative Research, 2022, 6, e33676.	2.3	6
30	A Digital Intervention Using Daily Financial Incentives to Increase Medication Adherence in Severe Mental Illness: Single-Arm Longitudinal Pilot Study. JMIR Mental Health, 2022, 9, e37184.	5.5	7
31	Cross-Platform Detection of Psychiatric Hospitalization via Social Media Data: Comparison Study. JMIR Mental Health, 2022, 9, e39747.	5.5	3
32	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophrenia Research, 2021, 227, 10-17.	2.4	33
33	Development and Validation of a Computerized Adaptive Assessment Tool for Discrimination and Measurement of Psychotic Symptoms. Schizophrenia Bulletin, 2021, 47, 644-652.	4.3	18
34	Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology. Journal of Medical Internet Research, 2021, 23, e18119.	5.3	10
35	Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia. Behavioural Brain Research, 2021, 402, 113099.	2.3	10
36	Antipsychotic Medications: Enhancing Use to Improve Outcomes. Schizophrenia Bulletin, 2021, 47, 1201-1204.	4.3	3

#	ARTICLE	IF	CITATIONS
37	A Social Media Study on Mental Health Status Transitions Surrounding Psychiatric Hospitalizations. Proceedings of the ACM on Human-Computer Interaction, 2021, 5, 1-32.	3.9	10
38	Authors'™ Reply to Suhas et al.: Comment on: "Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation". Clinical Pharmacokinetics, 2021, 60, 1077-1079.	3.7	0
39	Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1589-1597.	2.5	12
40	Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review. Journal of Psychopharmacology, 2021, 35, 1062-1073.	5.8	19
41	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-"post studies. Lancet Psychiatry,the, 2021, 8, 387-404.	9.0	211
42	Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. International Clinical Psychopharmacology, 2021, 36, 244-250.	1.7	23
43	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. Schizophrenia Bulletin, 2021, 47, 1621-1630.	4.3	31
44	mHealth-Assisted Detection of Precursors to Relapse in Schizophrenia. Frontiers in Psychiatry, 2021, 12, .	2.7	11
45	Psychoeducation for Inpatients With First-Episode Psychosis: Results From a Survey of Psychiatry Trainees in New York City. Psychiatric Services, 2021, 72, 582-585.	2.4	1
46	Music in behavioral health. , 2021, 84, 34-37.		0
47	Mental Health Care Providers'™ Attitudes Toward Telepsychiatry: A Systemwide, Multisite Survey During the COVID-19 Pandemic. Psychiatric Services, 2021, 72, 704-707.	2.4	73
48	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. Schizophrenia Bulletin, 2021, 47, 1611-1620.	4.3	48
49	Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2141-2150.	2.5	6
50	Long-acting injectable versus oral antipsychotics for schizophrenia " Authors' reply. Lancet Psychiatry,the, 2021, 8, 567.	9.0	2
51	Long-acting antipsychotics: is what we know really so? " Authors' reply. Lancet Psychiatry,the, 2021, 8, 651-652.	9.0	0
52	A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica, 2021, 144, 329-341.	4.7	38
53	Utilizing Instagram Data to Identify Usage Patterns Associated With Schizophrenia Spectrum Disorders. Frontiers in Psychiatry, 2021, 12, .	2.7	10
54	Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance. Schizophrenia Bulletin, 2021, 47, 1601-1610.	4.3	8

#	ARTICLE	IF	CITATIONS
55	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 986-996.	4.3	10
56	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. <i>CNS Drugs</i> , 2021, 35, 1189-1205.	6.8	40
57	Internet Search Activity of Young People With Mood Disorders Who Are Hospitalized for Suicidal Thoughts and Behaviors: Qualitative Study of Google Search Activity. <i>JMIR Mental Health</i> , 2021, 8, e28262.	5.5	6
58	How to Make an Effective Offer of Clozapine. <i>Journal of Clinical Psychiatry</i> , 2021, 83, .	2.9	3
59	Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, .	2.7	19
60	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. <i>Psychological Medicine</i> , 2020, 50, 1356-1367.	4.6	31
61	Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. <i>Schizophrenia Research</i> , 2020, 215, 408-415.	2.4	35
62	Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 225.	14.1	18
63	Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial. <i>Schizophrenia Research</i> , 2020, 215, 173-180.	2.4	8
64	Google search activity in early psychosis: A qualitative analysis of internet search query content in first episode psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 606-612.	2.2	8
65	Dose and safety concerns of clozapine: Worldwide package inserts need revisions. <i>Schizophrenia Research</i> , 2020, 216, 2-4.	2.4	17
66	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. <i>NPJ Schizophrenia</i> , 2020, 6, .	1.0	227
67	Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. <i>Schizophrenia Research</i> , 2020, 225, 55-62.	2.4	28
68	Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics. <i>Psychiatric Services</i> , 2020, 71, 337-342.	2.4	9
69	Incentivizing Is Not Coercing: A Commentary. <i>Psychiatric Services</i> , 2020, 71, 301-302.	2.4	5
70	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 749-761.	9.0	77
71	Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 1217.	14.1	133
72	Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview. <i>Indian Journal of Psychological Medicine</i> , 2020, 42, 4-10.	1.3	69

#	ARTICLE	IF	CITATIONS
73	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 141-145.	2.4	6
74	Natural History, Not Lead Time: Response to Srihari et al.. <i>American Journal of Psychiatry</i> , 2020, 177, 1185-1186.	10.5	2
75	T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS. <i>Schizophrenia Bulletin</i> , 2020, 46, S310-S310.	4.3	2
76	Adding Oral Contraceptives to Clozapine May Require Halving the Clozapine Dose. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 308-310.	2.0	16
77	The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, .	3.8	8
78	Edentulousness in severely mentally ill patients: A pilot study of sex-specific patterns for risk factors including the glutathione S-transferase M1 gene. <i>Schizophrenia Research</i> , 2020, 224, 178-179.	2.4	0
79	Identifying signals associated with psychiatric illness utilizing language and images posted to Facebook. <i>NPJ Schizophrenia</i> , 2020, 6, .	1.0	22
80	Lead-Time Bias as a Potential Explanation for the Link Between Duration of Untreated Psychosis and Outcome: Response to Iyer et al.. <i>American Journal of Psychiatry</i> , 2020, 177, 1181-1183.	10.5	2
81	Duration of Untreated Psychosis: Getting Both the Timing and the Sample Right: Response to Woods et al.. <i>American Journal of Psychiatry</i> , 2020, 177, 1183-1185.	10.5	5
82	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 222-223.	2.3	108
83	Clozapine and COVID-19: The authors respond. <i>Journal of Psychiatry and Neuroscience</i> , 2020, , E1-E2.	2.3	1
84	There is a non-evidence-based app for that: A systematic review and mixed methods analysis of depression- and anxiety-related apps that incorporate unrecognized techniques. <i>Journal of Affective Disorders</i> , 2020, 273, 410-421.	4.7	35
85	Prolactin changes during electroconvulsive therapy: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2020, 128, 25-32.	3.1	2
86	185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials. <i>CNS Spectrums</i> , 2020, 25, 316-317.	0.7	3
87	Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 875-883.	2.9	29
88	Using therapeutic drug monitoring to personalize clozapine dosing in Asians. <i>Asia-Pacific Psychiatry</i> , 2020, 12, .	2.5	32
89	Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. <i>Schizophrenia Research</i> , 2020, 218, 309-311.	2.4	0
90	Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia. <i>American Journal of Psychiatry</i> , 2020, 177, 327-334.	10.5	52

#	ARTICLE	IF	CITATIONS
91	Cultural Influences in Psychiatryâ€™Reply. JAMA - Journal of the American Medical Association, 2020, 323, 1193.	13.7	0
92	Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation. Clinical Pharmacokinetics, 2020, 60, 329-335.	3.7	27
93	Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. European Neuropsychopharmacology, 2020, 35, 1-11.	0.9	17
94	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. Focus (American Psychiatric Publishing), 2020, 18, 456-465.	1.3	9
95	Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study. JMIR Mental Health, 2020, 7, e19348.	5.5	10
96	Predicting Early Warning Signs of Psychotic Relapse From Passive Sensing Data: An Approach Using Encoder-Decoder Neural Networks. JMIR MHealth and UHealth, 2020, 8, e19962.	5.5	64
97	Patient Attitudes Toward Telepsychiatry During the COVID-19 Pandemic: A Nationwide, Multisite Survey. JMIR Mental Health, 2020, 7, e24761.	5.5	75
98	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. Journal of Clinical Psychiatry, 2020, 81, .	2.9	104
99	Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics. Journal of Clinical Psychiatry, 2020, 82, .	2.9	15
100	O8.2. VALIDATION OF A COMPUTERIZED ADAPTIVE TESTING TOOL FOR PSYCHOSIS: THE CAT-PSYCHOSIS BATTERY. Schizophrenia Bulletin, 2020, 46, S19-S19.	4.3	0
101	Identifying emerging mental illness utilizing search engine activity: A feasibility study. PLoS ONE, 2020, 15, e0240820.	2.5	7
102	Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study. Schizophrenia Research, 2019, 204, 271-281.	2.4	37
103	Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics. JAMA Psychiatry, 2019, 76, 1052.	14.1	101
104	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Review of Clinical Pharmacology, 2019, 12, 603-621.	2.9	75
105	Is Transcultural Psychiatry Possible?. JAMA - Journal of the American Medical Association, 2019, 322, 2167.	13.7	20
106	Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Movement Disorders, 2019, 34, 1203-1209.	5.3	22
107	Methodological Gaps in Predicting Mental Health States from Social Media. , 2019, , 1-16.		72
108	Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders. JAMA Psychiatry, 2019, 76, 1063.	14.1	52

#	ARTICLE	IF	CITATIONS
109	Capturing behavioral indicators of persecutory ideation using mobile technology. <i>Journal of Psychiatric Research</i> , 2019, 116, 112-117.	3.1	27
110	Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. <i>World Psychiatry</i> , 2019, 18, 208-224.	12.0	101
111	Predictors of Hospitalization of Individuals With First-Episode Psychosis: Data From a 2-Year Follow-Up of the RAISE-ETP. <i>Psychiatric Services</i> , 2019, 70, 569-577.	2.4	31
112	Longitudinal associations of family burden and patient quality of life in the context of first-episode schizophrenia in the RAISE-ETP study. <i>Psychiatry Research</i> , 2019, 276, 60-68.	3.4	13
113	Online help-seeking prior to diagnosis: Can web-based resources reduce the duration of untreated mood disorders in young people?. <i>Journal of Affective Disorders</i> , 2019, 252, 130-134.	4.7	22
114	Relationships between smartphone social behavior and relapse in schizophrenia: A preliminary report. <i>Schizophrenia Research</i> , 2019, 208, 167-172.	2.4	64
115	Structural similarity networks predict clinical outcome in early-phase psychosis. <i>Neuropsychopharmacology</i> , 2019, 44, 915-922.	5.4	28
116	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.9	183
117	Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2019, 33, 1201-1222.	6.8	24
118	Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 180-182.	2.0	10
119	Is there a trial bias impacting user engagement with unguided e-mental health interventions? A systematic comparison of published reports and real-world usage of the same programs. <i>Translational Behavioral Medicine</i> , 2019, , .	2.3	52
120	Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital. <i>Schizophrenia Research</i> , 2019, 206, 200-208.	2.4	20
121	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2019, 176, 21-28.	10.5	122
122	Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis. <i>Journal of Medical Internet Research</i> , 2019, 21, e14567.	5.3	484
123	Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics). <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.9	43
124	Clinical risk factors for the development of tardive dyskinesia. <i>Journal of the Neurological Sciences</i> , 2018, 389, 21-27.	1.4	104
125	Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. <i>Psychiatric Services</i> , 2018, 69, 590-592.	2.4	10
126	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 555.	14.1	568

#	ARTICLE	IF	CITATIONS
127	Factor structure of therapist fidelity to individual resiliency training in the Recovery After an Initial Schizophrenia Episode Early Treatment Program. <i>Microbial Biotechnology</i> , 2018, 12, 1052-1063.	2.2	4
128	Demographic and clinical correlates of substance use disorders in first episode psychosis. <i>Schizophrenia Research</i> , 2018, 194, 4-12.	2.4	76
129	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 603-619.	4.3	149
130	Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?. <i>Schizophrenia Research</i> , 2018, 193, 263-268.	2.4	19
131	Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study. <i>Schizophrenia Research</i> , 2018, 193, 64-68.	2.4	30
132	Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 369-377.	4.3	35
133	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , 2018, 175, 169-179.	10.5	51
134	Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis. <i>Schizophrenia Research</i> , 2018, 195, 481-487.	2.4	7
135	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , 2018, 195, 245-251.	2.4	40
136	Predictors of aggression in 3,322 patients with affective disorders and schizophrenia spectrum disorders evaluated in an emergency department setting. <i>Schizophrenia Research</i> , 2018, 195, 136-141.	2.4	13
137	Digital Trajectories to Care in First-Episode Psychosis. <i>Psychiatric Services</i> , 2018, 69, 1259-1263.	2.4	27
138	Disturbing Lack of Early Intervention Studies in Bipolar Disorder—Reply. <i>JAMA Psychiatry</i> , 2018, 75, 1202.	14.1	0
139	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , 2018, 17, 330-340.	12.0	144
140	Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1215-1238.	4.2	64
141	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , 2018, 17, 149-160.	12.0	209
142	Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics — expert consensus survey part 1. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1463-1474.	2.5	31
143	Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder — expert consensus survey part 2. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1475-1492.	2.5	24
144	Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel Dataset. <i>Journal of Medical Internet Research</i> , 2018, 20, e11491.	5.3	79

#	ARTICLE	IF	CITATIONS
145	Digital Peer-Support Platform (7Cups) as an Adjunct Treatment for Women With Postpartum Depression: Feasibility, Acceptability, and Preliminary Efficacy Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e38.	5.5	62
146	Revisiting the Abnormal Involuntary Movement Scale. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.9	37
147	Role of social media and the <sc>Internet in pathways to care for adolescents and young adults with psychotic disorders and non-ψpsychotic mood disorders. <i>Microbial Biotechnology</i> , 2017, 11, 290-295.	2.2	113
148	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	12.0	172
149	Home-Based Outpatient Telepsychiatry to Improve Adherence With Treatment Appointments: A Pilot Study. <i>Psychiatric Services</i> , 2017, 68, 743-746.	2.4	22
150	Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2017, 174, 886-894.	10.5	32
151	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 675.	14.1	166
152	Ω-3 Polyunsaturated Fatty Acids to Prevent Psychosis. <i>JAMA Psychiatry</i> , 2017, 74, 11.	14.1	11
153	CrossCheck: Integrating self-report, behavioral sensing, and smartphone use to identify digital indicators of psychotic relapse.. <i>Psychiatric Rehabilitation Journal</i> , 2017, 40, 266-275.	1.5	126
154	Accuracy of Clinician Assessments of Medication Status in the Emergency Setting. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 310-314.	2.0	31
155	Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia. <i>Neuropsychopharmacology</i> , 2017, 42, 2214-2221.	5.4	56
156	Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. <i>Schizophrenia Research</i> , 2017, 185, 167-172.	2.4	34
157	Clozapine Reduces All-Cause Mortality. <i>American Journal of Psychiatry</i> , 2017, 174, 920-921.	10.5	7
158	Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?. <i>NPJ Schizophrenia</i> , 2017, 3, .	1.0	13
159	Improving outcomes of first-episode psychosis: an overview. <i>World Psychiatry</i> , 2017, 16, 251-265.	12.0	405
160	Using Digital Media Advertising in Early Psychosis Intervention. <i>Psychiatric Services</i> , 2017, 68, 1144-1149.	2.4	33
161	Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income. <i>Schizophrenia Research</i> , 2017, 182, 120-128.	2.4	74
162	Linguistic Markers Indicating Therapeutic Outcomes of Social Media Disclosures of Schizophrenia. <i>Proceedings of the ACM on Human-Computer Interaction</i> , 2017, 1, 1-27.	3.9	65

#	ARTICLE	IF	CITATIONS
163	Enlight: A Comprehensive Quality and Therapeutic Potential Evaluation Tool for Mobile and Web-Based eHealth Interventions. <i>Journal of Medical Internet Research</i> , 2017, 19, e82.	5.3	145
164	A Collaborative Approach to Identifying Social Media Markers of Schizophrenia by Employing Machine Learning and Clinical Appraisals. <i>Journal of Medical Internet Research</i> , 2017, 19, e289.	5.3	126
165	Analyzing mHealth Engagement: Joint Models for Intensively Collected User Engagement Data. <i>JMIR MHealth and UHealth</i> , 2017, 5, e1.	5.5	50
166	Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and Be Most Promising for Predictive Algorithms for Conversion to Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e28-e40.	2.9	69
167	Dr Correll and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1062.	2.9	1
168	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1158-e1166.	2.9	5
169	Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e264-e278.	2.9	205
170	Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e957-e969.	2.9	43
171	Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1136-1147.	2.9	65
172	Assessing Patients for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1428.	2.9	3
173	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 72, 1-10.	2.5	29
174	Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 740-749.	2.0	87
175	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1418-1437.	4.3	137
176	Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. <i>Psychiatric Services</i> , 2016, 67, 1370-1372.	2.4	8
177	Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. <i>Schizophrenia Research</i> , 2016, 176, 220-230.	2.4	105
178	Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. <i>Psychiatric Services</i> , 2016, 67, 1035-1038.	2.4	21
179	Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 458-470.	2.0	19
180	Response to Amos: Addressing Purported Methodological Flaws in RAISE-ETP Results. <i>American Journal of Psychiatry</i> , 2016, 173, 535-536.	10.5	2

#	ARTICLE	IF	CITATIONS
181	The Role of Clozapine in Treatment-Resistant Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 187.	14.1	73
182	Mobile Behavioral Sensing for Outpatients and Inpatients With Schizophrenia. <i>Psychiatric Services</i> , 2016, 67, 558-561.	2.4	160
183	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 1091-1102.	3.4	24
184	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. <i>American Journal of Psychiatry</i> , 2016, 173, 362-372.	10.5	674
185	Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. <i>American Journal of Psychiatry</i> , 2016, 173, 69-77.	10.5	169
186	mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge. <i>JMIR Mental Health</i> , 2016, 3, e34.	5.5	102
187	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1-24.	2.9	288
188	Schizophrenia. <i>Nature Reviews Disease Primers</i> , 2015, 1, .	24.7	777
189	Patterns and predictors of medication discrepancies in primary care. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 831-839.	2.0	30
190	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	10.5	153
191	Response to Saraga. <i>American Journal of Psychiatry</i> , 2015, 172, 588-588.	10.5	0
192	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 718-727.e3.	0.6	33
193	Objective identification and analysis of physiological and behavioral signs of schizophrenia. <i>Journal of Mental Health</i> , 2015, 24, 276-282.	3.0	25
194	Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 5.	14.1	269
195	Ambiguous findings concerning potential advantages of depot antipsychotics. <i>Current Opinion in Psychiatry</i> , 2015, 28, 216-221.	4.9	48
196	The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. <i>Psychiatric Services</i> , 2015, 66, 680-690.	2.4	184
197	Duration of Untreated Psychosis in Community Treatment Settings in the United States. <i>Psychiatric Services</i> , 2015, 66, 753-756.	2.4	105
198	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 535-547.	2.0	7

#	ARTICLE	IF	CITATIONS
199	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. <i>Schizophrenia Bulletin</i> , 2015, 41, 1237-1247.	4.3	47
200	Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 1256-1265.	4.3	10
201	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , 2015, 41, 1227-1236.	4.3	96
202	Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002â€“2012). <i>Schizophrenia Research</i> , 2015, 168, 523-529.	2.4	18
203	Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 449-459.	4.3	59
204	Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study. <i>American Journal of Psychiatry</i> , 2015, 172, 52-58.	10.5	276
205	Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. <i>American Journal of Psychiatry</i> , 2015, 172, 237-248.	10.5	82
206	The Role of NMDA Receptors in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e01-e01.	2.9	4
207	The RAISE Early Treatment Program for First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 240-246.	2.9	125
208	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 1350.	14.1	317
209	Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies. <i>Schizophrenia Research</i> , 2014, 159, 415-420.	2.4	24
210	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. <i>Schizophrenia Bulletin</i> , 2014, 40, 192-213.	4.3	319
211	Antidepressants for cognitive impairment in schizophrenia â€” A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2014, 159, 385-394.	2.4	52
212	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. <i>Schizophrenia Research</i> , 2014, 152, 365-372.	2.4	18
213	Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients. <i>Schizophrenia Research</i> , 2014, 155, 72-76.	2.4	68
214	Rapid clozapine titration in treatment-refractory bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 168-172.	4.7	49
215	Attitudinal Barriers to Prescribing LAI Antipsychotics in the Outpatient Setting. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e33-e33.	2.9	9
216	Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. <i>Journal of Clinical Epidemiology</i> , 2013, 66, S37-S41.	4.0	104

#	ARTICLE	IF	CITATIONS
217	Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. <i>Schizophrenia Research</i> , 2013, 147, 95-102.	2.4	99
218	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. <i>World Psychiatry</i> , 2013, 12, 216-226.	12.0	359
219	Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 957-965.	2.9	360
220	Improving Patient Outcomes in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e18.	2.9	31
221	Termination of Clozapine Treatment Due to Medical Reasons. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 603-613.	2.9	200
222	Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients. <i>Neuropsychopharmacology</i> , 2011, 36, 1738-1746.	5.4	42
223	Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 106-115.	2.0	104
224	Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1115-1124.	2.9	183
225	Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 181-189.	10.5	170
226	Approaches to Treatment-Resistant Patients. , 2010, , 540-560.		1
227	Pharmacologic treatment of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 345-357.	5.6	90
228	Clinical guideline recommendations for antipsychotic long-acting injections. <i>British Journal of Psychiatry</i> , 2009, 195, s63-s67.	2.3	120
229	Cognitive deficits in schizophrenia: short-term and long-term. <i>World Psychiatry</i> , 2008, 7, 29-30.	12.0	7
230	Utilization of Long-Acting Antipsychotic Medication in Patient Care. <i>CNS Spectrums</i> , 2006, 11, 1-8.	0.7	28
231	Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). <i>Journal of Clinical Psychiatry</i> , 2006, 67, 831-832.	2.9	31
232	Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. <i>American Journal of Psychiatry</i> , 2004, 161, 414-425.	10.5	590
233	Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2003, 160, 1125-1132.	10.5	441
234	Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. <i>Schizophrenia Bulletin</i> , 2003, 29, 747-756.	4.3	17

#	ARTICLE	IF	CITATIONS
235	Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 763-771.	2.9	479
236	Side effects of antipsychotic drugs. <i>Postgraduate Medicine</i> , 2000, 107, 169-178.	2.8	13
237	Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors. <i>American Journal of Psychiatry</i> , 1998, 155, 1521-1528.	10.5	197
238	Methylphenidate Response, Psychopathology and Tardive Dyskinesia as Predictors of Relapse in Schizophrenia. <i>Neuropsychopharmacology</i> , 1994, 11, 107-118.	5.4	53
239	Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview. <i>British Journal of Psychiatry</i> , 1992, 160, 41-45.	2.3	142
240	The Prevalence of Tardive Dyskinesia. <i>Journal of Clinical Psychopharmacology</i> , 1991, 11, 34-42.	2.0	100
241	Obstacles to Clinical Research and New Drug Development in Schizophrenia. <i>Schizophrenia Bulletin</i> , 1991, 17, 353-356.	4.3	9
242	Research Diagnoses for Tardive Dyskinesia. <i>Archives of General Psychiatry</i> , 1982, 39, 486.	14.4	746
243	Awareness of illness moderates self-assessment of psychotic symptoms. <i>Australian and New Zealand Journal of Psychiatry</i> , 0, , 000486742110574.	2.7	1